Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use
HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.
Drugs
Health
Pharma